Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coryzalia is a multi-ingredient homeopathic medicine developed by Laboratoires Boiron, specifically formulated for the treatment of the common cold and associated upper respiratory tract symptoms. It is indicated for the relief of nasal congestion, runny nose, sneezing, acute or allergic rhinitis, hay fever, and sinusitis. The product contains a combination of six homeopathic active ingredients: Allium cepa, Belladonna, Gelsemium sempervirens, Kalium bichromicum, Pulsatilla, and Sabadilla, each at a 3CH dilution. As a homeopathic preparation, it is designed to stimulate the body's natural healing processes rather than targeting specific molecular biological receptors. Coryzalia is available in various forms, including orodispersible tablets and drinkable unit-dose vials, and is marketed for use in both adults and children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Coryzalia.